Re:Amygdala connectivity predicts ketamine treatment respons...
by chimeracoder on Monday November 28, 2022 @01:56PM
(#33777887)
> Ketamine is normally dosed based on body weight[0]. For depression IV, the dose is 0.1–0.75mg/kg/40mins, most commonly 0.5mg/kg/40mins
If we're being specific, the FDA-approved treatment of ketamine for depression is a fixed 84mg dose. It is not adjusted for body weight.
(I did invite irony by saying that it wasn't a typo - it's 84 and 56 for redoing, not 86 and 54).
Re:Amygdala connectivity predicts ketamine treatment respons...
by csnover on Tuesday November 29, 2022 @11:28PM
(#33797033)
Thanks for the clarification! Since you’d mentioned IM administration it didn’t cross my mind that you were talking about Spravato. That typo is regrettable, but unimportant to your point that the nasal spray does indeed use two fixed doses.
To clarify: my understanding is that ketamine acts as a dissociative hallucinogen at lower doses and an anaesthetic at higher doses, so taking a higher dose will just knock someone out instead of giving them the dissociative/hallucinogenic effects.
> The clinical dose for depression is 86mg (not a typo), which is sometimes doubled, and the clinical dose for anesthetic purposes (which is what ketamine is mostly used for) is between 500mg-1g. The latter is IM injection, so it's also much more bioavailable than the first two (ie, the effective dose differential is even higher).
Ketamine is normally dosed based on body weight[0]. For depression IV, the dose is 0.1–0.75mg/kg/40mins, most commonly 0.5mg/kg/40mins. Clinical use in IM seems to be less consistent, with some clinicians using the same range and others doubling it, so the 86mg could be used for a wide range of body weights.
[0] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6023575/table/T...
[1] https://www.psychiatrist.com/jcp/depression/ketamine-for-dep...